BDK Advokati’s counsel Bisera Andrijašević and Associate Anja Gligorević authored the chapter on Serbia featured among 23 jurisdictions in the 2023 edition of the Chambers’ Global Practice Guide on Life Sciences. We have taken a snapshot of the life sciences regulatory landscape in Serbia in the current dynamic global regulatory climate. The EU pharmaceutical legislation is undergoing the biggest transformation in more than 20 years, and the proposed extensive changes could eventually have a profound effect as well on industry players doing business in Serbia as a candidate country. Serbia is becoming increasingly attractive to pharmaceutical companies, and the expected legislative changes should accelerate that process through synchronisation of the legal framework with advances brought by the digital transformation.
The Serbian chapter gives an overview of the topics such as the challenging the decisions of regulatory bodies, conduct of clinical trials and related data protection issues, the marketing, manufacturing and distribution of pharmaceuticals and medical devices, pricing of medicines, digital healthcare, and patents. We will keep the online chapter updated in line with any notable changes of the regulatory regime.
To access the entire guide online, use the following link: Life Science 2023.
